Evidence map›Paper›PMID 40855123›Full record

ArticleNature biomedical engineering2026

Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline.

Mark Buckup, Igor Figueiredo, Giorgio Ioannou, Sinem Ozbey, Rafael Cabal, Alexandra Tabachnikova, Leanna Troncoso, Jessica Le Berichel, Zhen Zhao, Stephen C Ward and 13 more

Abstract read
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mark BuckupMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-6938-3474
Igor Figueiredo *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giorgio Ioannou *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7956-7605
Sinem OzbeyMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rafael CabalMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alexandra TabachnikovaMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Leanna TroncosoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-2529-9267
Jessica Le BerichelMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhen ZhaoDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stephen C WardDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clotilde HennequinMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Guray AkturkMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7032-8085
Steve HamelMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Maria Isabel FielDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rachel BrodyDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Myron SchwartzDepartment of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-9113-886X
Thomas U MarronMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5903-8191
Seunghee Kim-SchulzeMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0192-4400
Vladimir RoudkoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Edgar Gonzalez-KozlovaMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pauline HamonMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6776-1635
Miriam MeradMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4481-7827
Sacha GnjaticMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. sacha.gnjatic@mssm.edu.ORCID http://orcid.org/0000-0001-5643-9520

Funding

Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4M
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5M
ERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0M
Investigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4M
Dissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3M
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9M
PRIMAVO: Interactive exploration of cancer patient precision immune monitoring data in clinical trialsR33CA263705 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GUMUS, ZEYNEP HULYA · 2021 to 2021
$1.5M
NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA154947NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R33 CA263705NCI NIH HHS U24 CA224319NIDDK NIH HHS U01 DK124165U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA154947U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA254104U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA257195U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA196521U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R33CA263705U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U24CA224319U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UL1TR004419U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) U01DK124165
6 · The paper itself

Abstract

Multiplex immunostaining analysis remains fragmented, underperforming and labour intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, user-guided automated pipeline that streamlines start-to-finish, single-cell resolution analysis of whole-slide tissue, named multiplex-imaging analysis, registration, quantification and overlaying (MARQO). MARQO integrates elastic image registration, iterative nuclear segmentation, unsupervised clustering with mini-batch k-means and user-guided cell classification through a graphical interface. We compare and validate MARQO using multiplexed immunohistochemical consecutive staining on a single slide using human tumour and adjacent normal tissue samples. Performance is compared with manually curated pathologist determinations and quantification of multiple markers. We optimize MARQO to analyse diverse tissue sizes from whole tissue, biopsy, and tissue microarray and staining approaches, such as singleplex immunohistochemistry and 20-colour multiplex immunofluorescence, to determine marker co-expression patterns in multiple human solid cancer types. Lastly, we validate CD8

Indexed as

Image Processing, Computer-AssistedNeoplasmsBiomarkers, TumorCarcinoma, HepatocellularCD8-Positive T-LymphocytesHumansImmunohistochemistrySingle-Cell AnalysisTissue Array AnalysisBiomarkers, Tumor

Identifiers

PMID40855123
PMCPMC13008776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.